Expand ENVB Menu
ENVB MENU

ENVB Latest Press Releases

-- June 2, 2026 --

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 Business Wire 8:00 AM

-- May 19, 2026 --

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 Business Wire 8:00 AM

-- May 15, 2026 --

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 Business Wire 8:00 AM

-- May 13, 2026 --

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders Business Wire 8:00 AM

-- May 5, 2026 --

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model Business Wire 8:00 AM

-- April 28, 2026 --

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PRNewswire 7:33 AM

-- April 21, 2026 --

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum Business Wire 8:00 AM

-- April 17, 2026 --

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules Business Wire 6:28 PM

-- April 16, 2026 --

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules Business Wire 8:00 PM

-- March 31, 2026 --

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates Business Wire 8:00 AM

-- March 27, 2026 --

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 Business Wire 5:40 PM

-- March 18, 2026 --

Enveric Biosciences Announces Registration of Five Trademarks Business Wire 8:00 AM

-- February 25, 2026 --

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent Business Wire 8:00 AM

-- February 19, 2026 --

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data Business Wire 8:00 AM

-- January 29, 2026 --

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option Business Wire 8:00 AM

-- January 28, 2026 --

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire 5:00 PM
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire 8:00 AM
Market Data Delayed 15 Minutes